Cite
MLA Citation
Francesca Ferrari et al.. “Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.” Journal of experimental & clinical cancer research, vol. 34, no. 1, 2015, pp. 1–8. http://access.bl.uk/ark:/81055/vdc_100080280643.0x000048